The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Celgene's 2013 oncology sales performance.
The company added that after discussions with its partner Celgene it had "decided not to move forward with the ROCKET trial or JCAR015 at this time, even though it generated important
Celgene bags US priority review for cancer metabolism drug. First approval for enasidenib could be just six months away. ... IDH2 mutations occur in around 8-19% of AML patients, according to Celgene.
As expected, the larger big pharma companies tend to be in the top rank in the number of in-licensing deals but smaller companies like Boehringer Ingelheim and Celgene punched well ... Meanwhile Celgene, with sales around 20% of those of Pfizer, did
|Oncology revenue 2014|
|4: Johnson & Johnson|
|5: Bristol-Myers Squibb|
|9: Merck & Co.|
|16: Merck KGaA|
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com